PBAC's latest decision on Naloxone: Recommended (2019). Considered for Emergency treatment for known or suspected opioid overdose manifested by respiratory and/or central nervous system depression in the home, other non-medical settings, or health facility settings.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Adults at risk of or likely to witness opioid overdose, suitable for use in the home or non-medical settings as part of emergency treatment for opioid overdose.
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
Single-arm
Primary endpoint
Pharmacokinetic equivalence
Pivotal trial size
38 patients
Key trials
McDonald et al. 2017, Kelly et al. 2005, Kerr et al. 2009
Comparator
naloxone 1 mg/mL injection, 2 mL prefilled syringe
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis on basis of equivalent cost per treatment to injectable naloxone; no ICER calculated